Bianchi Porro G, Parente F
Gastrointestinal Unit, L. Sacco Hospital, Milan, Italy.
Scand J Gastroenterol Suppl. 1990;174:48-53. doi: 10.3109/00365529009091930.
Recent years have witnessed significant progress in antacid therapy of duodenal ulcer disease, consisting in the demonstration that the doses required for ulcer healing are much smaller and less frequent that those regarded as necessary or optimal in the past. Antacids at these dosages proved to be as effective as H2-blockers both in terms of healing capacity and in relieving ulcer symptoms and are associated with negligible gastrointestinal side-effects. In addition, there has been a renewed interest in the tablet formulation, which now appears more acceptable to the patient. All these characteristics make antacids competitive with other anti-ulcer agents, especially in terms of the cost/benefit ratio.
近年来，十二指肠溃疡病的抗酸治疗取得了显著进展，这体现在已证实溃疡愈合所需的剂量比过去认为必要或最佳的剂量要小得多且服用频率更低。事实证明，这些剂量的抗酸剂在愈合能力和缓解溃疡症状方面与H2阻滞剂一样有效，并且胃肠道副作用可忽略不计。此外，人们对片剂剂型重新产生了兴趣，现在片剂似乎更易被患者接受。所有这些特性使抗酸剂与其他抗溃疡药物相比具有竞争力，尤其是在成本效益比方面。
